CellTivity Scientific Announces Presentation of Two Real-World Studies at ATS 2025 Demonstrating the Impact of Dynamic Cell Imaging in Robotic Bronchoscopy
Waltham, MA — [Insert Date] — CellTivity Scientific, a pioneer in real-time biopsy assessment technology, today announced the presentation of two independent, investigator-led studies at the 2025 American Thoracic Society (ATS) International Conference. The research — conducted at the University of Pittsburgh Medical Center (UPMC) and University of Chicago Medical Center — highlights the value of the Van Gogh™ Microscopy System and its Dynamic Cell Imaging (DCI) technology in supporting intra-procedural biopsy adequacy assessment during robotic bronchoscopy.
The presentations highlight real-world use of DCI in both robotic and peripheral bronchoscopy procedures, offering evidence that the VanGogh System can help improve biopsy adequacy, reduce indeterminate samples, and support faster, more confident clinical decisions, all without disrupting workflow or compromising tissue for downstream testing.
UPMC Study: Real-Time Assessment of Lesional Material in Peripheral Lung Biopsies
Presentation: Use of the Van Gogh System to Assess for Intra-Procedural Tissue Adequacy: Initial Experience
Presenter: Dr. Christopher Nemeh, University of Pittsburgh Medical Center
Session: A79 – From IP to Precision Treatment: Cutting-Edge Research
Date & Time: Sunday, May 18 | 11:30 AM – 1:15 PM | Area H, Hall F(Exhibition Level)
This prospective study evaluated 51 robotic bronchoscopy cases at UPMC using DCI to determine sample adequacy and tissue quality. In all cases confirmed malignant on final pathology, DCI identified sufficient material for molecular testing. The study demonstrated that DCI can provide real-time visualization of cellular morphology and metabolic activity, preserving the integrity of tissue for downstream analysis.
Key Findings:
- DCI identified adequate tissue for molecular testing in all confirmed malignant cases (100% concordance)
- DCI preserved sample integrity and did not interfere with downstream testing
- Enabled proceduralists to quantify lesional material and assess cellular activity intra-procedurally
University of Chicago Study: DCI vs. ROSE in Robotic Biopsy Workflows
Presentation: Dynamic Cell Imaging as an Alternative to Rapid Onsite Evaluation in Robotic Bronchoscopy: A Comparative Study
Presenter: Dr. Rachel Deitz, University of Chicago Medical Center
Session: C31 – Breaking Through the Fog: AI, IP and Novel Insights to Improve Lung Cancer Diagnosis and Management
Date & Time: Tuesday, May 20 | 9:15 – 11:15 AM | Room 3010/3012
This comparative study evaluated 94 robotic bronchoscopy cases in a head-to-head comparison between DCI and Rapid Onsite Evaluation(ROSE). DCI demonstrated superior interpretation rates, reduced indeterminate biopsies, and faster procedures. Notably, DCI identified malignancies in 12cases where ROSE had called samples benign—confirmed later on resection.
Key Findings:
- DCI successfully interpreted 98% of samples vs. 54% for ROSE (p < 0.001)
- Procedure times were significantly shorter with DCI (42 vs. 53 minutes, p < 0.001)
- Indeterminate biopsy rate was reduced by more than half (4.3% vs. 11%, p = 0.04)
- DCI detected malignancy in 12 cases missed by ROSE, confirmed on follow-up pathology
“These studies underscore the clinical utility of DCI as areal-time solution for biopsy adequacy during bronchoscopy,” said Greg Bowles, CEO.“Van Gogh is providing physicians with data they’ve never had at the point of care; enabling faster, more informed decisions and higher diagnostic confidence without disrupting the workflow.”
About CellTivity Scientific
CellTivity Scientific is advancing the standard of care in tissue diagnostics through real-time, metabolic assessment of biopsy samples. The Van Gogh™ Microscopy System uses Dynamic Cell Imaging (DCI), an advanced computational imaging algorithm that quantifies cellular metabolic activity in real time. By capturing and overlaying dynamic cellular motion on traditional morphology, DCI provides proceduralists with immediate insight into suspicions for malignancy, enabling confident decisions without compromising tissue for downstream testing.
